Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171923 | 0.93 | PDE10A (0.46) | GPR119GFERCASP6PIK3CDPDE10A | |
| SCHEMBL31142600 | 0.88 | GPR119 (0.47) | GPR119NPY5RPDE10AHSD11B1AAK1 | |
| SCHEMBL16580729 | 0.87 | GPR119 (0.50) | GPR119GFERCASP6 | |
| SCHEMBL5536857 | 0.87 | NPY5R (0.52) | GPR119NPY5RPDE10AKMT2A | |
| SCHEMBL28155287 | 0.87 | NPY5R (0.52) | GPR119PIK3CDNPY5RPDE10AHSD11B1 | |
| SCHEMBL27624495 | 0.87 | CASP6 (0.39) | GPR119GFERCASP6PDE10AHSD11B1 | |
| SCHEMBL24872991 | 0.86 | GPR119 (0.48) | GPR119PIK3CDNPY5RPDE10AHSD11B1 | |
| SCHEMBL30888812 | 0.86 | GPR119 (0.48) | GPR119PIK3CDNPY5RPDE10AHSD11B1 | |
| SCHEMBL20046230 | 0.86 | USP2 (0.55) | GPR119NPY5RPDE10AHSD11B1USP30 | |
| SCHEMBL5543855 | 0.86 | NOTUM (0.49) | GPR119AAK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. | 2025-01-16 | — | — | US | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-06-13 | — | — | US | disclosed |
| CN-117957225-A | Compounds for targeting degradation of IRAK4 proteins | 渤健马萨诸塞州股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4313989-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117377673-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | GPR119 2911/4885GFER 4489/4885CASP6 1106/4885 |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GPR119 39/4885GFER 1433/4885CASP6 3996/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GPR119 39/4885GFER 1433/4885CASP6 3996/4885 |
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, HIPK3 | GPR119 626/4885GFER 4772/4885CASP6 3223/4885 |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, PGK1 | GPR119 408/4885GFER 4759/4885CASP6 3412/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | GPR119 948/4885GFER 4197/4885CASP6 2105/4885 |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | PDXK, HIPK1, HIPK3 | GPR119 626/4885GFER 4772/4885CASP6 3223/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | GPR119 3162/4885GFER 4358/4885CASP6 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.